ATE203907T1 - Dermatologische zubereitung zur behandlung von aktinischen keratosen - Google Patents

Dermatologische zubereitung zur behandlung von aktinischen keratosen

Info

Publication number
ATE203907T1
ATE203907T1 AT96912861T AT96912861T ATE203907T1 AT E203907 T1 ATE203907 T1 AT E203907T1 AT 96912861 T AT96912861 T AT 96912861T AT 96912861 T AT96912861 T AT 96912861T AT E203907 T1 ATE203907 T1 AT E203907T1
Authority
AT
Austria
Prior art keywords
treatment
actinic keratosis
dermatological preparation
composition
dermatological
Prior art date
Application number
AT96912861T
Other languages
English (en)
Inventor
Bruce E Katz
Original Assignee
Bruce E Katz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bruce E Katz filed Critical Bruce E Katz
Application granted granted Critical
Publication of ATE203907T1 publication Critical patent/ATE203907T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
AT96912861T 1995-04-12 1996-04-10 Dermatologische zubereitung zur behandlung von aktinischen keratosen ATE203907T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/421,674 US5627187A (en) 1995-04-12 1995-04-12 5-FU for treating actinic kerotoses
PCT/US1996/005346 WO1996032112A1 (en) 1995-04-12 1996-04-10 Dermatological preparation and method for treating actinic keratoses

Publications (1)

Publication Number Publication Date
ATE203907T1 true ATE203907T1 (de) 2001-08-15

Family

ID=23671557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912861T ATE203907T1 (de) 1995-04-12 1996-04-10 Dermatologische zubereitung zur behandlung von aktinischen keratosen

Country Status (12)

Country Link
US (2) US5627187A (de)
EP (1) EP0822816B1 (de)
AT (1) ATE203907T1 (de)
AU (1) AU707853B2 (de)
CA (1) CA2215840A1 (de)
DE (1) DE69614375T2 (de)
DK (1) DK0822816T3 (de)
ES (1) ES2162051T3 (de)
GR (1) GR3037031T3 (de)
IL (1) IL117882A0 (de)
PT (1) PT822816E (de)
WO (1) WO1996032112A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
IL140005A0 (en) * 1998-06-26 2002-02-10 Aventis Pharm Prod Inc Method of treatment for dermatological disorders and compositions therefor
US7220414B2 (en) * 2000-09-06 2007-05-22 A.P. Pharma, Inc. Degradable polyacetal polymers
US6670335B2 (en) 2001-03-05 2003-12-30 A. P. Pharma, Inc. Fluorouracil-containing formulation
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
AU2003234670B2 (en) * 2002-05-24 2010-06-10 Angiotech International Ag Compositions and methods for coating medical implants
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
ES2402522T3 (es) 2005-11-22 2013-05-06 Orexigen Therapeutics, Inc. Composiciones y procedimientos para aumentar la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
EP2143421A1 (de) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Zusammensetzung zur topischen Behandlung von Strahlenkeratose
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) * 1957-08-06 S-eluorourace
US2000213A (en) * 1932-07-18 1935-05-07 Standard Brands Inc Process for the manufacture of hydroxy carboxylic acids
US2265945A (en) * 1938-04-09 1941-12-09 Du Pont Organic acid synthesis
US2382889A (en) * 1941-07-22 1945-08-14 Lock Ritchie Hart Manufacture of lactic acid and salts thereof
US2970084A (en) * 1958-01-21 1961-01-31 Miles Lab Production of citric acid by fermentation
US3114770A (en) * 1959-01-20 1963-12-17 Orandi & Massera Sa Ind & Com Recovery of tartaric acid, as the calcium salt, from wine dregs
US2972566A (en) * 1959-12-07 1961-02-21 Kyowa Hakko Kogyo Kk Process for the production of l-malic acid
US3063910A (en) * 1960-02-03 1962-11-13 Kyowa Hakko Kogyo Kk Method of producing l-malic acid by fermentation
US3274074A (en) * 1963-10-24 1966-09-20 Kerr Mc Gee Oil Ind Inc Preparation of salicyclic acid by microbiological oxidation of naphthalene in the presence of a boron compound
US4363815A (en) * 1975-07-23 1982-12-14 Yu Ruey J Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5326790A (en) * 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
EP0443028B1 (de) * 1989-01-05 1993-09-29 Otsuka Pharmaceutical Co., Ltd. Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
DE19549330A1 (de) * 1995-02-17 1996-08-22 Boehringer Mannheim Gmbh Mittel zur Behandlung von Nagelpilz
DE19505328C1 (de) * 1995-02-17 1996-06-20 Boehringer Mannheim Gmbh Verwendung von Fluoruracil zur Behandlung von Nagelpilz

Also Published As

Publication number Publication date
ES2162051T3 (es) 2001-12-16
MX9707850A (es) 1998-08-30
EP0822816B1 (de) 2001-08-08
AU5553596A (en) 1996-10-30
AU707853B2 (en) 1999-07-22
EP0822816A4 (de) 1998-12-30
IL117882A0 (en) 1996-08-04
CA2215840A1 (en) 1996-10-17
PT822816E (pt) 2002-01-30
DK0822816T3 (da) 2001-11-12
GR3037031T3 (en) 2002-01-31
US5627187A (en) 1997-05-06
DE69614375T2 (de) 2002-05-23
WO1996032112A1 (en) 1996-10-17
DE69614375D1 (de) 2001-09-13
EP0822816A1 (de) 1998-02-11
US5817666A (en) 1998-10-06

Similar Documents

Publication Publication Date Title
ATE203907T1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
AU2080988A (en) Esters of 13-trans-retinoic acid
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
ES2155473T3 (es) Composicion veterinaria que contiene un inhibidor de las bombas de protones.
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
MY104412A (en) Acne treatment.
WO1998008461A3 (en) Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
NO983864L (no) Morfin- og diamorfinsalter av anioniske, ikke-narkotiske analgetika av den substituerte karboksyltypen
FI925944A (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
ES2006121A6 (es) Procedimiento para la preparacion de una composicion farmaceutica destinada al tratamiento de enfermedades cutaneas.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE195430T1 (de) Niedrig dosierte steroidtabletten, die gallussäureester als antioxidans enthalten, verfahren zur herstellung und die verwendung
NO972558L (no) Sett for osteoporose-behandlingssyklus
NO952904L (no) Lysinsalt av 6-klor-5-fluor-3-(2-tenoyl)-2-oxindol-1-karboksamide
DE3991360T1 (de) Verfahren zur herstellung von wasserloeslichem primycin und seinen komponenten sowie von diese enthaltenden pharmazeutischen praeparaten
RU95119892A (ru) Способ выделения цистеиновых катепсинов из экстрактов тканей
BE900654A (fr) Composition pharmaceutique et procede de traitement de l'excitation.
DE68905479D1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
UA23098A (uk) Спосіб приготуваhhя морфологічhих препаратів для імуhоцитохімічhого досліджеhhя
UA18225A (uk) Спосіб лікуваhhя раh
MA25278A1 (fr) Procede de therapie des maladies cardiovasculaires utilisant des derives d'aminotetraline.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee